277 related articles for article (PubMed ID: 37346803)
1. Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy.
Grodzka A; Knopik-Skrocka A; Kowalska K; Kurzawa P; Krzyzaniak M; Stencel K; Bryl M
EXCLI J; 2023; 22():415-432. PubMed ID: 37346803
[TBL] [Abstract][Full Text] [Related]
2. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin DJ; Haslam A; Gill J; Prasad V
Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
[TBL] [Abstract][Full Text] [Related]
4. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
Steeghs EMP; Groen HJM; Schuuring E; Aarts MJ; Damhuis RAM; Voorham QJM; ; Ligtenberg MJL; Grünberg K
Lung Cancer; 2022 May; 167():87-97. PubMed ID: 35461050
[TBL] [Abstract][Full Text] [Related]
5. Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.
Kuang X; Xiao J; Dai LX; Zhang LH; He BX
Transl Cancer Res; 2019 Jun; 8(3):736-751. PubMed ID: 35116812
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O
Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of first-line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations.
Uehara Y; Watanabe K; Hakozaki T; Yomota M; Hosomi Y
Thorac Cancer; 2022 Jun; 13(11):1703-1711. PubMed ID: 35491960
[TBL] [Abstract][Full Text] [Related]
8. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
9. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
[TBL] [Abstract][Full Text] [Related]
10. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
[No Abstract] [Full Text] [Related]
11. New horizons for uncommon mutations in non-small cell lung cancer:
Olmedo ME; Cervera R; Cabezon-Gutierrez L; Lage Y; Corral de la Fuente E; Gómez Rueda A; Mielgo-Rubio X; Trujillo JC; Couñago F
World J Clin Oncol; 2022 Apr; 13(4):276-286. PubMed ID: 35582653
[TBL] [Abstract][Full Text] [Related]
12. Targeting molecular alterations in non-small-cell lung cancer: what's next?
López-Castro R; García-Peña T; Mielgo-Rubio X; Riudavets M; Teixidó C; Vilariño N; Couñago F; Mezquita L
Per Med; 2022 Jul; 19(4):341-359. PubMed ID: 35748237
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic alterations in advanced NSCLC: a molecular super-highway.
Friedlaender A; Perol M; Banna GL; Parikh K; Addeo A
Biomark Res; 2024 Feb; 12(1):24. PubMed ID: 38347643
[TBL] [Abstract][Full Text] [Related]
14. Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
Sun S; Du W; Sun Q; Zhao X; Qin B; Shi D; Wan C; Wu Z
Cancer Med; 2021 Oct; 10(20):7360-7372. PubMed ID: 34599863
[TBL] [Abstract][Full Text] [Related]
15. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics of
Dugay F; Llamas-Gutierrez F; Gournay M; Medane S; Mazet F; Chiforeanu DC; Becker E; Lamy R; Léna H; Rioux-Leclercq N; Belaud-Rotureau MA; Cabillic F
Oncotarget; 2017 Aug; 8(32):53336-53351. PubMed ID: 28881815
[TBL] [Abstract][Full Text] [Related]
17. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
Wang Z; Xing Y; Li B; Li X; Liu B; Wang Y
Mol Biomed; 2022 Dec; 3(1):42. PubMed ID: 36508072
[TBL] [Abstract][Full Text] [Related]
19.
Dong YU; Ren W; Qi J; Jin BO; Li Y; Tao H; Xu R; Li Y; Zhang Q; Han B
Oncol Lett; 2016 Apr; 11(4):2371-2378. PubMed ID: 27073482
[TBL] [Abstract][Full Text] [Related]
20. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally?
Ou SH; Soo RA; Kubo A; Kawaguchi T; Ahn MJ
Front Oncol; 2014; 4():58. PubMed ID: 24744988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]